Consensus on precision medicine for metastatic cancers: a report from the MAP conference

Research output: Contribution to journalArticlepeer-review


  • C Swanton
  • J-C Soria
  • A Bardelli
  • A Biankin
  • C Caldas
  • S Chandarlapaty
  • L de Koning
  • C Dive
  • J Feunteun
  • S-Y Leung
  • R Marais
  • E R Mardis
  • N McGranahan
  • S A Quezada
  • J Rodón
  • N Rosenfeld
  • C Sotiriou
  • F André

Colleges, School and Institutes

External organisations

  • Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London UCL Hospitals and Cancer Institute, London, UK.
  • Drug Development Unit, Gustave Roussy, Villejuif Department of Medical Oncology, INSERM Unit U981, Faculté de medicine Paris-Sud XI, Kremlin-Bicêtre, Villejuif, France.
  • Department of Oncology, University of Torino, Candiolo, Torino Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Department of Translational Research, Institut Curie, PSL Research University, Paris, France.
  • University of Manchester
  • Stabilité Génétique et Oncogenèse, Université Paris-Sud, Gustave-Roussy, Villejuif, France.
  • Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
  • McDonnell Genome Institute, Washington University School of Medicine, St Louis, USA.
  • King's College London
  • University College London
  • Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • University of Cambridge
  • Breast Cancer Translational Research Laboratory-BCTL (ULB 290), Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.


Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The first MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. Sixteen consensus items were covered. There was a consensus that new technologies like next-generation sequencing of tumors and ddPCR on circulating free DNA have convincing analytical validity. Further work needs to be undertaken to establish the clinical utility of liquid biopsies and the added clinical value of expanding from individual gene tests into large gene panels. Experts agreed that standardized bioinformatics methods for biological interpretation of genomic data are needed and that precision medicine trials should be stratified based on the level of evidence available for the genomic alterations identified.


Original languageEnglish
Pages (from-to)1443-1448
Number of pages6
JournalAnnals of Oncology
Issue number8
Early online date3 May 2016
Publication statusPublished - Aug 2016